CN1181886C - Tnf来源的肽在治疗水肿中的应用 - Google Patents

Tnf来源的肽在治疗水肿中的应用 Download PDF

Info

Publication number
CN1181886C
CN1181886C CNB998096555A CN99809655A CN1181886C CN 1181886 C CN1181886 C CN 1181886C CN B998096555 A CNB998096555 A CN B998096555A CN 99809655 A CN99809655 A CN 99809655A CN 1181886 C CN1181886 C CN 1181886C
Authority
CN
China
Prior art keywords
tnf
peptide
edema
amino acids
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB998096555A
Other languages
English (en)
Chinese (zh)
Other versions
CN1312724A (zh
Inventor
R������¬��
R·卢卡斯
P·德贝特赛利尔
J·普金
A·布洛克
�������ɭ
L·弗兰森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rudolf Lucas
Original Assignee
Innogenetics NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics NV SA filed Critical Innogenetics NV SA
Publication of CN1312724A publication Critical patent/CN1312724A/zh
Application granted granted Critical
Publication of CN1181886C publication Critical patent/CN1181886C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/191Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CNB998096555A 1998-08-14 1999-08-10 Tnf来源的肽在治疗水肿中的应用 Expired - Lifetime CN1181886C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP98870180 1998-08-14
EP98870180.1 1998-08-14
EP98870198.3 1998-09-18
EP98870198 1998-09-18
EP98870222.1 1998-10-21
EP98870222 1998-10-21

Publications (2)

Publication Number Publication Date
CN1312724A CN1312724A (zh) 2001-09-12
CN1181886C true CN1181886C (zh) 2004-12-29

Family

ID=27239778

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998096555A Expired - Lifetime CN1181886C (zh) 1998-08-14 1999-08-10 Tnf来源的肽在治疗水肿中的应用

Country Status (20)

Country Link
US (2) US20030105021A1 (enExample)
EP (3) EP1247531B1 (enExample)
JP (1) JP4542266B2 (enExample)
CN (1) CN1181886C (enExample)
AT (2) ATE395072T1 (enExample)
AU (1) AU764992B2 (enExample)
BR (1) BR9912899A (enExample)
CA (1) CA2334941C (enExample)
CZ (1) CZ302862B6 (enExample)
DE (2) DE69938743D1 (enExample)
DK (1) DK1264599T3 (enExample)
ES (1) ES2296872T3 (enExample)
HU (1) HU227661B1 (enExample)
IL (2) IL141064A0 (enExample)
NZ (1) NZ509604A (enExample)
PL (1) PL203706B1 (enExample)
PT (1) PT1264599E (enExample)
TR (1) TR200100338T2 (enExample)
WO (1) WO2000009149A1 (enExample)
ZA (1) ZA200100656B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ509604A (en) 1998-08-14 2003-05-30 Innogenetics N TNF-derived peptides for use in treating oedema
EP1781323B1 (en) 2004-08-06 2010-02-17 Nycomed GmbH Composition comprising a pulmonary surfactant and a tnf-derived peptide
EP2009023A1 (en) * 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema
AT506150B1 (de) 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Zyklisches und cystein-freies peptid
AT506151B1 (de) 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Fusionsprotein
AT507953B1 (de) * 2009-03-05 2011-02-15 Apeptico Forschung & Entwicklung Gmbh Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität
AT509267A1 (de) * 2010-01-14 2011-07-15 Apeptico Forschung & Entwicklung Gmbh Organische verbindungen zur regulierung von vektoriellen ionenkanälen
DK2397151T3 (en) 2010-06-21 2015-05-18 Apeptico Forschung & Entwicklung Gmbh The treatment of the vascular complications of diabetes
AT510585B1 (de) * 2010-11-18 2012-05-15 Apeptico Forschung & Entwicklung Gmbh Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase
US11161881B2 (en) * 2010-11-18 2021-11-02 Apeptico Forschung Und Entwicklung Gmbh Composition comprising a peptide and an inhibitor of viral neuraminidase
EP2679239A1 (de) * 2012-06-28 2014-01-01 Apeptico Forschung und Entwicklung GmbH Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit
US12004506B2 (en) 2013-04-23 2024-06-11 Apeptico Forschung Und Entwicklung Gmbh Pharmaceutical composition comprising a cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment
JP6335279B2 (ja) * 2013-04-23 2018-05-30 アペプティコ フオルシユング ウント アントウィクラング ゲーエムベーハー 式x1−gqretpegaeakpwy−x2の環状ペプチドを含んでなる医薬組成物および体外肺処置のための使用
JP6397984B2 (ja) 2014-03-18 2018-09-26 アペプティコ・フォルシュング・ウント・エントヴィックルング・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングApeptico Forschung Und Entwicklung Gmbh 乾燥粉末ペプチド医薬
CN110613838A (zh) * 2018-06-19 2019-12-27 姜石松 增强细胞通透性的多肽及其应用
IL280880B2 (en) 2018-08-27 2025-04-01 Regeneron Pharma Using Raman Spectroscopy in Downstream Purification
EP4051307B1 (en) 2020-05-08 2023-02-01 APEPTICO Forschung und Entwicklung GmbH Peptide for prevention or treatment of covid-19

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE384179C (de) * 1921-04-07 1923-10-27 Ludwig Weil Dr Laufrad fuer Kreiselpumpen und -geblaese
DE3841759A1 (de) 1988-12-12 1990-06-13 Basf Ag Neue tnf-peptide
CA2155103A1 (en) * 1993-02-03 1994-08-18 Rudolph Lucas Tnf-alpha muteins and a process for preparing them
NZ509604A (en) 1998-08-14 2003-05-30 Innogenetics N TNF-derived peptides for use in treating oedema

Also Published As

Publication number Publication date
DK1264599T3 (da) 2008-02-04
JP4542266B2 (ja) 2010-09-08
EP1247531A2 (en) 2002-10-09
EP1264599A1 (en) 2002-12-11
PL345997A1 (en) 2002-01-14
ZA200100656B (en) 2005-06-29
IL141064A0 (en) 2002-02-10
EP1105152A1 (en) 2001-06-13
ATE395072T1 (de) 2008-05-15
EP1247531B1 (en) 2008-05-14
CA2334941A1 (en) 2000-02-24
BR9912899A (pt) 2001-05-08
PT1264599E (pt) 2008-01-07
IL141064A (en) 2009-09-01
PL203706B1 (pl) 2009-11-30
HU227661B1 (hu) 2011-10-28
NZ509604A (en) 2003-05-30
TR200100338T2 (tr) 2001-12-21
US7258861B2 (en) 2007-08-21
CZ302862B6 (cs) 2011-12-21
CN1312724A (zh) 2001-09-12
EP1264599B1 (en) 2007-09-26
DE69938743D1 (de) 2008-06-26
HUP0103117A2 (hu) 2001-12-28
US20030105021A1 (en) 2003-06-05
AU764992B2 (en) 2003-09-04
DE69937206T2 (de) 2008-06-19
DE69937206D1 (de) 2007-11-08
CZ2001538A3 (cs) 2001-08-15
HUP0103117A3 (en) 2004-03-01
EP1247531A3 (en) 2002-12-18
JP2002522508A (ja) 2002-07-23
ATE374039T1 (de) 2007-10-15
CA2334941C (en) 2011-08-09
ES2296872T3 (es) 2008-05-01
HK1051805A1 (en) 2003-08-22
AU5620999A (en) 2000-03-06
WO2000009149A1 (en) 2000-02-24
US20030185791A1 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
CN1181886C (zh) Tnf来源的肽在治疗水肿中的应用
EP2633865B1 (en) Use of interleukin-22 in treating viral hepatitis
EP2152738B1 (en) Novel peptides and their use for the treatment of edema
JPH05502161A (ja) 組換えヒト8因子誘導体
JP2015057058A (ja) 組織傷害の修復におけるストロマ細胞由来因子1のプロテアーゼ耐性変異体
KR20090005300A (ko) 펩티드 및 펩티드 유도체와 이들을 함유하는 약학적 조성물
US20020165161A1 (en) Chemokine-binding proteins for treating congestive heart failure
JP5967631B2 (ja) 上皮及び内皮損傷の治療剤
CN1469756A (zh) 治疗肝病的药物
WO1996011700A1 (en) Reduction of mammalian neoplasms with phospholipase a2 activatiing substances
HK1051802A (en) Tnf-derived peptides for use in treating oedema
HK1051805B (en) Tnf-derived peptides for use in treating oedema
MXPA01001527A (en) Tnf-derived peptides for use in treating oedema
JP5791022B2 (ja) 細胞遊走調節剤
JP2010120937A (ja) ヒトアポリポタンパク質a−iiのアミノ酸断片又はその改変体を含有する炎症性疾患予防・治療剤
CN1448405A (zh) 人截短型重组可溶性trail-170蛋白及其在制备肿瘤治疗药物中的应用
JPH03291238A (ja) 角膜障害治療剤
JPH03277284A (ja) 遺伝子及びその製造法
CA2480423A1 (en) Truncated 24 kda basic fibroblast growth factor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: RUDOLF LUCAS

Free format text: FORMER OWNER: INNOGENETICS NV

Effective date: 20070817

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20070817

Address after: Belgium aartselaar

Patentee after: Rudolf Lucas

Address before: Ghent

Patentee before: Innogenetics N.V.

CX01 Expiry of patent term

Granted publication date: 20041229

CX01 Expiry of patent term